Grail shares surge after FDA staff see no major test concerns
US FDA staff reviewers said they did not raise major concerns about the accuracy and safety of Grail’s multi-cancer blood test. Grail’s shares surged 35% on Monday.
US FDA staff reviewers did not raise major concerns about the accuracy and safety of Grail's NASDAQ:GRAL blood test designed to detect more than 50 cancers, sending the company's shares up 35% on Monday. The screening test was called a breakthrough by the company, according to the source text.